Abstract
Given the continued burden of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) disease (COVID-19) across the U.S., there is a high unmet need for data to inform decision-making regarding social distancing and universal masking. We examined the association of community-level social distancing measures and individual masking with risk of predicted COVID-19 in a large prospective U.S. cohort study of 198,077 participants. Individuals living in communities with the greatest social distancing had a 31% lower risk of predicted COVID-19 compared with those living in communities with poor social distancing. Self-reported masking was associated with a 63% reduced risk of predicted COVID-19 even among individuals living in a community with poor social distancing. These findings provide support for the efficacy of mask-wearing even in settings of poor social distancing in reducing COVID-19 transmission. In the current environment of relaxed social distancing mandates and practices, universal masking may be particularly important in mitigating risk of infection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Zoe provided in kind support for all aspects of building, running and supporting the app and service to all users worldwide. ADJ is supported by the National Institute of Diabetes and Digestive and Kidney Diseases K01DK110267. DAD is supported by the National Institute of Diabetes and Digestive and Kidney Diseases K01DK120742. CMA is supported by the NIDDK K23-DK120899. LHN is supported by the American Gastroenterological Association Research Scholars Award. ATC is the Stuart and Suzanne Steele MGH Research Scholar and Stand Up to Cancer scientist. The Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz supported MGH investigators (SK, ADJ, CHL, DAD, LHN, CGG, WM, RSM, JM, ATC). King's College of London investigators (KAL, MNL, TV, MG, CHS, MJC, SO, CJS, TDS) were supported by the Wellcome Trust and EPSRC (WT212904/Z/18/Z, WT203148/Z/16/Z, T213038/Z/18/Z), the NIHR GSTT/KCL Biomedical Research Centre, MRC/BHF (MR/M016560/1), UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, and the Alzheimer's Society (AS-JF-17-011). MNL is supported by an NIHR Doctoral Fellowship (NIHR300159). JM is partially supported by the European Commission Horizon 2020 program (H2020-MSCA-IF-2015-703787) and by the National Institutes of Health (P30 DK40561). JEH is supported by NIH/NIEHS P30 ES000002. TV is supported by NIH/NIDDK K01 DK125612. Sponsors had no role in study design, analysis, and interpretation of data, report writing, and the decision to submit for publication. The corresponding author had full access to data and the final responsibility to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research study was approved by the Partners Human Research Committee (Institutional Review Board Protocol 2020P000909).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICT OF INTEREST JW, RD, and JC are employees of Zoe Global Ltd. TDS is a consultant to Zoe Global Ltd. DAD, JM, and ATC previously served as investigators on a clinical trial of diet and lifestyle using a separate mobile application that was supported by Zoe Global Ltd. Other authors have no conflict of interest to declare.
FUNDING Zoe provided in kind support for all aspects of building, running and supporting the app and service to all users worldwide. ADJ is supported by the National Institute of Diabetes and Digestive and Kidney Diseases K01DK110267. DAD is supported by the National Institute of Diabetes and Digestive and Kidney Diseases K01DK120742. CMA is supported by the NIDDK K23-DK120899. LHN is supported by the American Gastroenterological Association Research Scholars Award. ATC is the Stuart and Suzanne Steele MGH Research Scholar and Stand Up to Cancer scientist. The Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz supported MGH investigators (SK, ADJ, CHL, DAD, LHN, CGG, WM, RSM, JM, ATC). King’s College of London investigators (KAL, MNL, TV, MG, CHS, MJC, SO, CJS, TDS) were supported by the Wellcome Trust and EPSRC (WT212904/Z/18/Z, WT203148/Z/16/Z, T213038/Z/18/Z), the NIHR GSTT/KCL Biomedical Research Centre, MRC/BHF (MR/M016560/1), UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, and the Alzheimer’s Society (AS-JF-17-011). MNL is supported by an NIHR Doctoral Fellowship (NIHR300159). JM is partially supported by the European Commission Horizon 2020 program (H2020-MSCA-IF-2015-703787) and by the National Institutes of Health (P30 DK40561). JEH is supported by NIH/NIEHS P30 ES000002. TV is supported by NIH/NIDDK K01 DK125612. Sponsors had no role in study design, analysis, and interpretation of data, report writing, and the decision to submit for publication. The corresponding author had full access to data and the final responsibility to submit for publication.
Data Availability
Data collected in the app are being shared with other health researchers through the NHS-funded Health Data Research UK (HDRUK)/SAIL consortium, housed in the UK Secure e-Research Platform (UKSeRP) in Swansea. Anonymized data can be shared with bonafide researchers via HDRUK, provided the request is made according to their protocols and is in the public interest (see https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6). Data updates can be found at https://covid.joinzoe.com.
